We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

This study is currently recruiting participants.
Verified May 2017 by Kevin Kalinsky, Columbia University
Sponsor:
ClinicalTrials.gov Identifier:
NCT02066532
First Posted: February 19, 2014
Last Update Posted: May 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Incyte Corporation
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Kevin Kalinsky, Columbia University
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2018
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)

To Top